Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03972293 · ClinicalTrials.gov registry record · NA
2018 Intern Health Study Micro-randomized Trial
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 2,134
- Enrollment target
NCT03972293: Completed NA study, sponsored by University of Michigan.
NCT03972293 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 2,134 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03972293, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,134 participants
- Enrollment target
Study Summary
The aim of this trial is to evaluate the efficacy of an intervention (delivered through a smartphone) for improving the mood, physical activity, and sleep of medical interns.
Primary Outcome
Through the mobile app, participants enter a mood score (scale 1-10) every day of the study. 1 corresponds to lowest mood and 10 corresponds to highest mood For interns randomized to arm 1, average daily moods scores on weeks when a specific category of notification is sent are compared to mood scores on weeks when no notifications are sent.
Interventions
- BEHAVIORAL Intern Health Study behavioral change mobile notification
- BEHAVIORAL Intern Health Study mobile app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,134 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2019-07-01 |
| Phase | NA |
What the finished NCT03972293 record still lists
NCT03972293 is an interventional study that assigns participants to a tested intervention. Its 2,134 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (52% higher).
The record links to 0 conditions, and to 2 interventions - of which Intern Health Study behavioral change mobile notification is the first listed.
NCT03972293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03972293 about?
NCT03972293 is a clinical study titled "2018 Intern Health Study Micro-randomized Trial". The aim of this trial is to evaluate the efficacy of an intervention (delivered through a smartphone) for improving the mood, physical activity, and sleep of medical interns.
What is the current status of trial NCT03972293?
This trial is currently completed. It is a NA study. The enrollment target is 2,134 participants. The study started on 2018-04-01. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT03972293?
The interventions under investigation include: Intern Health Study behavioral change mobile notification (BEHAVIORAL), Intern Health Study mobile app (BEHAVIORAL).
Who is sponsoring clinical trial NCT03972293?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03972293's enrollment target sits among peer trials
2,134 49th of 2000 higher than 1,952 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI